Just as generic drugs have dramatically lowered the price of some common medicines and expanded access to them, so follow-on versions of complex biologic drugs to treat diseases like cancer and multiple sclerosis could benefit patients and reduce costs.
NIBR scientists do mini-sabbaticals with clinical researchers at other sites. Learn how they refresh their skills and boost scientific research.
Sandoz, the generic division of Novartis, is working with a local partner in Brazil which is undertaking the first clinical trial in that country for a biosimilar drug.
Interview with Mahesh P. Karande, Head of the Africa Cluster for Novartis. In this role, he is responsible for leading Novartis business activities in sub-Saharan Africa.
Novartis teams test combinations of targeted therapeutic agents to combat drug resistance in tumors.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.